In lab tests researchers have created a metal-based molecule that inhibits the build-up of a peptide associated with Alzheimer’s disease
A peptide is a fragment of a protein, and one of the key hallmarks of Alzheimer's disease is the build-up of a specific peptide known as amyloid-β. Some metal-based molecules have been previously designed to prevent amyloid-β from building up. However, these are often toxic to cells, or are unable to cross the blood-brain barrier (BBB) – a semi-permeable protective barrier that carefully regulates the passage of substances that enter and exit the brain. Now, a team from the Departments of Chemistry and Bioengineering at Imperial College London have designed a metal-based molecule that is highly effective at preventing the build-up of amyloid-β in lab-based studies. They also showed that the molecule is non-toxic to human brain-like cells, and that it can cross the blood-brain barrier in mice with the help of a technique using microbubbles and focused ultrasound. The results are reported in the journal Chemical Science.
First author Tiffany Chan, from the Departments of Chemistry and Bioengineering at Imperial, said: “Very few metal-based molecules have been investigated as potential inhibitors of amyloid-β build-up because of toxicity issues and difficulty crossing the blood brain barrier. "The molecule we have designed is able to interfere with amyloid-β and seems non-toxic, and it can be delivered across the blood brain barrier using ultrasound, which means you don’t need an invasive procedure.” The molecule is centred around the metal cobalt, surrounded by organic molecules that form a complex, which binds to amyloid-β peptides, preventing them from binding to each other and building up. The molecule also incorporates chemical groups that prevent it from being taken up into human nerve cells, reducing its toxicity.
To demonstrate the molecule could cross the BBB, the team used a technique that involves injecting the molecule alongside microbubbles into the veins of mice. When ultrasound is directed at the brain, the microbubbles rapidly move back and forth, opening the BBB and allowing the molecule to enter the brain in a non-invasive and targeted manner. The team were able to focus the ultrasound on the hippocampal region of the brain, which is often strongly impacted by the build-up of amyloid-β in the early stages of Alzheimer's disease. They were also able to show how specific the ultrasound targeting can be by delivering the molecule only to the left hippocampus. The research is published in the journal Chemical Science.
Source: imperial College London news release